A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China
NCT ID: NCT05606302
Last Updated: 2022-11-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
14000 participants
OBSERVATIONAL
2021-10-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI
NCT06636890
Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China
NCT05002582
Identification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.
NCT03569917
Longitudinal and Cross-sectional Analysis of Pulmonary Microbiota in Lung Transplant Recipients Infected With Nocardia
NCT06594133
Emergence of Gram-negative Resistance in Blood Culture Isolates of Solid-organ Transplant Recipients
NCT00304330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Piperacillin group
Blood samples for hemolytic anemia in patients treated with piperacillin were screened for the production of drug antibodies.
No interventions assigned to this group
Amoxicillin group
Blood samples for hemolytic anemia in patients treated with amoxicillin were screened for the production of drug antibodies.
No interventions assigned to this group
Cefazolin group
Blood samples for hemolytic anemia in patients treated with cefazolin were screened for the production of drug antibodies.
No interventions assigned to this group
Cefuroxime group
Blood samples for hemolytic anemia in patients treated with cefuroxime were screened for the production of drug antibodies.
No interventions assigned to this group
Ceftriaxone group
Blood samples for hemolytic anemia in patients treated with ceftriaxone were screened for the production of drug antibodies.
No interventions assigned to this group
Cefoxitin sodium group
Blood samples for hemolytic anemia in patients treated with cefoxitin sodium were screened for the production of drug antibodies.
No interventions assigned to this group
Vancomycin group
Blood samples for hemolytic anemia in patients treated with vancomycin were screened for the production of drug antibodies.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No limitation on age or sex;No limitation on nationality;Regional unlimited;
* Participates treated with one or more of the drugs including piperacillin, amoxicillin, cefazolin, cefuroxime, ceftriaxone, cefoxitin sodium, and vancomycin.
Exclusion Criteria
* Sample of severe hemolysis;
* Jaundice sample;
* The sample is cloudy and may be contaminated with bacteria;
* The source of the sample is unknown and cannot be traced;
* Patients with a history of medication who were deemed inappropriate to participate in this study were evaluated by the researchers.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanfang Hospital, Southern Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nanfang hospital of southern medical university
Guangzhou, Gaungdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NFEC-2019-164
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.